文献速递肝病

慢性丙型肝炎持续病毒学应答对患者报告结局的长期获益

Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-07-31

该研究比较了慢性HCV感染患者中达成与未达成持续病毒学应答(SVR)者治疗后的患者报告结局(PRO)评分。纳入4234例SVR和242例非SVR患者,随访至96周。SVR患者所有PRO评分较基线显著升高并持续,非SVR患者PRO评分下降。多因素分析显示SVR与所有SF-36领域评分独立相关。

要点

  • 达成SVR的慢性HCV患者所有PRO评分较治疗前基线显著升高(均P<.05)。
  • 未达成SVR者随访期间PRO评分平均降低≤9.2分(8个SF-36领域中4-8个P<.05)。
  • 多因素分析中SVR与所有SF-36领域评分独立相关(β +4.8至+15.9分,均P≤.01)。

核心结论

  • 慢性HCV感染患者达成SVR后,基于PRO评分的健康状况显著改善并持续。
  • 未达成SVR的患者在随访期间PRO评分下降。

研究设计与样本

  • 对完成临床试验治疗的患者,根据治疗结局纳入2个注册研究(NCT01457755、NCT01457768)。
  • 2016至2017年在北美、欧洲和亚太地区17个国家入组。
  • 分析纳入4234例SVR患者和242例非SVR患者,均有治疗前PRO数据;平均年龄54±10岁,63%男性,65%在美国入组,17%肝硬化,12% HIV共感染。
  • 使用SF-36量表(评分0-100)在治疗前基线、治疗最后一天、治疗后第12周随访(仅SVR患者)、注册基线及注册第12、24、36、48、96周(非SVR注册)或每24周直至第96周(SVR注册)收集PRO评分。

主要发现

  • 入注册时,SVR患者所有PRO评分较治疗前基线显著升高(均P<.05)。
  • 非SVR患者在注册随访期间PRO评分平均降低≤9.2分(8个SF-36领域中4-8个P<.05)。
  • SVR患者在注册期间PRO评分持续升高(平均升高≤7.0分)。
  • 多因素分析中,达成SVR与所有SF-36领域在所有注册时间点的更优评分独立相关(β +4.8至+15.9分,均P≤.01)。

临床怎么用

  • 在临床随访中,达成SVR的慢性HCV患者报告的健康状况改善可持续至治疗后96周。
  • 未达成SVR的患者报告的健康状况在随访期间呈下降趋势。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with hepatitis C virus (HCV) infections who achieve a sustained virologic response (SVR) to treatment have improved patient-reported outcomes (PROs). We compared post-treatment PRO scores between patients with chronic HCV infection who did and did not achieve an SVR to treatment. METHODS: Patients who completed treatment in clinical trials were enrolled in 2 registries, depending on the treatment outcome (NCT01457755, NCT01457768), from 2016 to 2017 in 17 countries in North America, Europe, and the Asia-Pacific region. PRO scores (scale, 0-100) were collected at pretreatment (baseline); the last day of treatment; the post-treatment week 12 follow-up visit (in patients with SVR only); the registry baseline; and on registry weeks 12, 24, 36, 48, and 96 (the non-SVR registry) or every 24 weeks until week 96 (SVR registry), using the Short Form-36 (SF-36) instrument. RESULTS: Our analysis included 4234 patients with an SVR and 242 without an SVR from whom pretreatment PRO data were available (mean age, 54 ± 10 y; 63% male; 65% enrolled in the United States; 17% with cirrhosis; 12% with human immunodeficiency virus co-infection). Upon registry enrollment, patients with an SVR had significant increases in all PRO scores compared with pretreatment baseline levels (all P < .05). Patients without an SVR had mean reductions of 9.2 points or less in PRO scores while followed up on the registry (P < .05 for 4-8 of 8 PRO domains measured by the SF-36). In contrast, patients with an SVR had sustained increases in PRO scores (mean increase, ≤7.0 points) while on the registry. In multivariate analysis, achieving an SVR was associated independently with superior scores in all SF-36 domains at all registry time points (β, +4.8 to +15.9 points, all P ≤ .01). CONCLUSIONS: In a follow-up analysis of participants in clinical trials, we found that those with an SVR to treatment for HCV infection had significant increases in well-being, based on PRO scores. Patients without an SVR had decreasing PRO scores over the follow-up period.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Stepanova M, Racila A, et al. Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. Clin Gastroenterol Hepatol. 2019. PMID: 31376493. doi:10.1016/j.cgh.2019.07.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。